Jakarta, 29 May 2023 Through our Community-Led Monitoring (CLM) of Viral Hepatitis services, we found that since 2019 there have been several stockouts of Hepatitis C medicines. The most current one is the stock-out of Daclatasvir since early April 2023. Today, Peduli Hati Bangsa together with other community organizations carry out an action to ask…
Category: All-id
Below is a report on the achievements of the Yayasan Peduli Hati Bangsa’s screening services for 2022
The following is the Report on the Progress of HIV/AIDS and Sexually Transmitted Infectious Diseases in the fourth quarter of 2021 released by the Ministry of Health.
Categories
Anak dengan HIV di tengah pandemi
One of the groups most affected during the COVID-19 pandemic is children. Even outside of the pandemic period, children have vulnerabilities: vulnerable to illness, vulnerable to violence, and vulnerable to being mistreated by adults. In the framework of World AIDS Day 2021, the Health Collaborative Center collaborated with Lentera Anak Pelangi and Yayasan Peduli Hati…
11 June 2021By: Liz Highleyman On June 10, 2021, the US Food and Drug Administration (FDA) extended its approval for Epclusa (sofosbuvir/velpatasvir) and Mavyret (glecaprevir/pibrentasvir) for the treatment of hepatitis C in children 3 years of age and older. Both combinations are effective against all genotypes of hepatitis C virus (HCV).Hepatitis C is rare in…